Erik van Meegen

Characteristics of Anticoagulant Therapy and Comorbidity Related to Overanticoagulation

Fernie Penning-van Beest, Erik van Meegen, Frits R. Rosendaal et al. · Thrombosis and Haemostasis · 2001 · 134 citations

Medicine, Hematology, Pharmacology +17

VKORC1 and CYP2C9 Genotypes and Phenprocoumon Anticoagulation Status: Interaction Between both Genotypes Affects Dose Requirement

Tom Schalekamp, B.P. Brassé, Janine Roijers et al. · Clinical Pharmacology & Therapeutics · 2006 · 102 citations

Medicine, Pharmacology, Pharmacotherapy +14

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

Rianne MF van Schie, Judith A.M. Wessels, Saskia le Cessie et al. · European Heart Journal · 2011 · 97 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon

Alain Gadisseur, Edwin Pasterkamp, F.J.M. van der Meer et al. · Thrombosis and Haemostasis · 2003 · 93 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs

Fernie J. A. Penning‐van Beest, Erik van Meegen, Frits R. Rosendaal et al. · Clinical Pharmacology & Therapeutics · 2001 · 63 citations

Pharmacy, Pharmacology, Pharmacotherapy +16